Identification and Determination of Flunitrazepam and Its Metabolites in Blood by Gas Chromatography

Total Page:16

File Type:pdf, Size:1020Kb

Identification and Determination of Flunitrazepam and Its Metabolites in Blood by Gas Chromatography Chem. Anal. (Warsaw), 49, 71 (2004) Identification and Determination of Flunitrazepam and Its Metabolites in Blood by Gas Chromatography by Zofia Ch³obowska1, Czes³awa wiegoda1, Pawe³ Kocielniak1,2* and Wojciech Piekoszewski1 1 Institute of Forensic Research, ul. Westerplatte 9, 31033 Cracow 2 Faculty of Chemistry, Jagiellonian University, ul. R. Ingardena 3, 30060 Cracow Key words: flunitrazepam, metabolites, gas chromatography Analytical method for the isolation of flunitrazepam and its metabolites (desmethyl- flunitrazepam and 7-amino-flunitrazepam) from blood involving liquid-liquid extraction with diethyl ether, diisopropyl ether and toluene-isoamyl alcohol mixture (95:5) has been developed. In the latter case the extraction yield approached 80%. The analysis of the com- pounds was performed using gas chromatograph with electron capture detector, and a HP1 column. The developed method allowed one to determine flunitrazepam and its metabolites at the level as low as few nanograms. Opracowano metodê analityczn¹ pozwalaj¹c¹ na ekstrakcyjne wyizolowanie flunitrazepamu i jego metabolitów (desmetyloflunitrazepamu i 7-aminoflunitrazepamu) z krwi przy u¿yciu eteru dietylowego, eteru diizpropylowego lub mieszaniny toluenu z alkoholem izoamylowym (95:5). W ostatnim przypadku osi¹gniêto wydajnoæ na poziomie 80%. Do analizy wymie- nionych substancji zastosowano chromatografiê gazow¹ z detektorem wychwytu elektronów oraz kolumnê HP1. Opracowana metoda pozwala wykrywaæ zawartoæ flunitrazepamu i jego metabolitów we krwi na poziomie kilku nanogramów. * Corresponding author. E-mail: [email protected] 72 Z. Ch³obowska, C. wiegoda, P. Kocielniak and W. Piekoszewski Flunitrazepam (Rohypnol), the fluoro derivative of benzodiazepine, is a sedative and hypnotic drug. It is easily absorbed from alimentary tract and undergoes biotrans- formation via N-dimethylation, hydroxylation and reduction with moderate rapidity [1]. It is used for the treatment of insomnia, as a preanesthetic agent in surgical opera- tions, and in intensive therapy. Flunitrazepam acts synergistically with muscle rela- xants and intensifies depressive effect of drugs inhibiting the central nervous system activity [2]. When taken with alcohol may cause anterograde amnesia and even death. Therefore its influence on humans is investigated in forensic toxicology [35]. Since its introduction to the pharmaceutical market in 1975 flunitrazepam was overused in many countries in America, Australia, Asia and Europe mostly by heroin addicts, since it boosts the effect of heroin or even replaces it when the latter is not available. In order to cause intoxication, flunitrazepam may be taken independently, or in com- bination with alcohol or other drugs orally, intravenously or by inhalation in the form of powdered tablets. Although flunitrazepam is a legal medicament in Poland, it is also smuggled from abroad. Police statistics indicate that the drug is used to intoxicate women before the rape. For that purpose the drug is given secretly, usually mixed with alcohol. Gradu- ally, depending on the doses administered, a loss of consciousness appears, and in consequence of anterograde amnesia victims do not remember what has happened to them. These circumstances necessitated the determination of flunitrazepam in biologi- cal material to meet the needs of forensic investigations and clinical toxicology. Flunitrazepam and its metabolites may be detected and determined in biological fluids (blood, urine) and hair. The most commonly used analytical methods for the detection are high-pressure liquid and gas chromatographies. Gas chromatography with electron capture detector is sensitive towards flunitrazepam and desmethyl-fluni- trazepam, but not to 7-amino-flunitrazepam. GCMS technique requires derivatisation of 7-amino-flunitrazepam before its determination. HPLC with UV detection is not enough sensitive to perform determination of these drugs at therapeutical concentra- tions [510]. Among sample preparation methods the leading group involves liquid- liquid and solid phase extraction techniques. The aim of this study was to develop a suitable analytical procedure for the detec- tion of traces of flunitrazepam and its metabolites in blood. The work includes optimisation of the separation conditions of flunitrazepam, desmethyl-flunitrazepam, and 7-amino-flunitrazepam, elaboration of their extraction procedure from blood, and evaluation of the influence of biological matrix putrefaction on the results of the analyses. Identification and determination of flunitrazepam in blood 73 EXPERIMENTAL Chromatographic separation of flunitrazepam and its metabolites At first it was indispensable to work out the optimum conditions for chromatographic separation of flunitrazepam and its metabolites desmethyl-flunitrazepam and 7-amino-flunitrazepam. In order to do so one prepared 50 ng mL-1 methanolic solutions of the given drug and its metabolites, individually and in the mixture. The solutions were introduced into a megabore chromatographic column HP1 30 m × 0.53 mm (1.5 µm). The analyses were performed using a FISONS GC 8000 gas chromatograph equipped with elec- tron capture detector (EC). Helium was passed through the system as a carrier gas at a flow rate of 15 mL min-1. The temperature of EC detector was kept at 300°C and of the injector at 250°C. The separation of the investigated drugs was carried out at the temperature of 240°C. Development of a blood extraction procedure To develop the extraction procedure of the examined compounds from blood, standard blood samples containing 50 ng mL-1 of flunitrazepam, desmethyl-flunitrazepam, and 7-amino-flunitrazepam have been prepared. The applicability of diethyl ether, diisopropyl ether and a mixture of toluene with isoamyl alcohol (95:5) for the extraction has been examined. 5 µL of 50 ng mL-1 flurazepam solution (internal standard), 200 µL of phosphate buffer, and 1 mL of the extracting agent were added to 0.2 mL of blood sample containing flunitrazepam and its metabolites. The buffer provided the pH at the level of 7.4 in the case of diethyl ether and diisopropyl ether, and at 7.8 when the mixture of tolueneisoamyl alcohol was used. The contents were shaken for 60 s, next centrifuged, and finally the organic phase was separated and extracted again with 400 µL of phosphate buffer solution for 30 s. After that the aqueous phase was removed, while the organic one was evaporated under the stream of nitrogen at a temperature of 37°C. The residue was dissolved in 500 µL of methanol before introducing it to the sample injector. Evaluation of the influence of biological matrix on the determination of flunitrazepam A composition of a matrix of fresh blood sample taken from a living person and a corpse, and a decayed blood sample taken from a corpse were examined employing the extraction procedure described above. An autopsic blood sample with added flunitrazepam was also analysed. In each case five different blood samples have been analysed. Validation of the determination procedure of flunitrazepam In order to estimate the extraction recovery of flunitrazepam from blood and to examine the repeatabil- ity of the proposed analytical procedure, blood samples free from examined drugs and containing the analyte at three different concentrations (20, 50, and 100 ng mL-1) were prepared and extracted according to the procedures described above. The samples of a given concentration of the analyte were subjected to the extraction with diethyl ether, diisopropyl ether and a mixture of toluene with isoamyl alcohol. After extrac- tion flurazepam was introduced to the solutions as an internal standard. Moreover, three methanolic standard solutions containing the analyte and the internal standard at the same concentrations as the extracted samples have been prepared. The signals obtained for the extracted and standard solutions were compared in order to calculate the extraction recovery. The measurement was performed five-fold for each sample extracted and the results were averaged to get the final value. 74 Z. Ch³obowska, C. wiegoda, P. Kocielniak and W. Piekoszewski Detection limits of the examined drugs were determined as usual from the peak heights of the internal standard, and the noise signals referring to five different points on a peak baseline of each drug [11]. Next step was to estimate the concentration range of flunitrazepam within which the measured analyti- cal signals changed linearly. Thus, blood samples free from the examined drugs and containing flurazepam as the internal standard and the analyte at the concentration ranging from 10 to 200 ng mL-1 were subjected to the extraction (using diethyl ether, diisopropyl ether and a mixture of toluene with isoamyl alcohol as extracting agents). After the extraction of each sample was completed, the analyte and the internal standard were determined in few consecutive analyses, and the average value was taken for further calculations. RESULTS AND DISCUSSION Under the optimum conditions, the retention times and the relative retention times for flunitrazepam and its metabolites were determined and compared with the respec- tive values for flurazepam (internal standard). Alcoholic solution containing the stud- ied compounds at the concentration of 50 ng mL-1 was directly injected to the chro- matographic column. Exemplary chromatogram of the sample is shown in Figure 1. 7-amino-flunitrazepam 5.100 flunitrazepam desmetyl-flunitrazepam flurazepam 2 4 6 8 10 12 14 16 min Detector signal, AU 0 2 4 6 8 10 12 14 16
Recommended publications
  • Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
    International Journal of Molecular Sciences Article Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors Hana Kubová 1,* , Zde ˇnkaBendová 2,3 , Simona Moravcová 2,3 , Dominika Paˇcesová 2,3, Luisa Rocha 4 and Pavel Mareš 1 1 Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic; [email protected] 2 Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (Z.B.); [email protected] (S.M.); [email protected] (D.P.) 3 National Institute of Mental Health, 25067 Klecany, Czech Republic 4 Pharmacobiology Department, Center of Research and Advanced Studies, Mexico City 14330, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +420-2-4106-2565 Received: 31 March 2020; Accepted: 28 April 2020; Published: 30 April 2020 Abstract: Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7–11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex.
    [Show full text]
  • Appendix D: Important Facts About Alcohol and Drugs
    APPENDICES APPENDIX D. IMPORTANT FACTS ABOUT ALCOHOL AND DRUGS Appendix D outlines important facts about the following substances: $ Alcohol $ Cocaine $ GHB (gamma-hydroxybutyric acid) $ Heroin $ Inhalants $ Ketamine $ LSD (lysergic acid diethylamide) $ Marijuana (Cannabis) $ MDMA (Ecstasy) $ Mescaline (Peyote) $ Methamphetamine $ Over-the-counter Cough/Cold Medicines (Dextromethorphan or DXM) $ PCP (Phencyclidine) $ Prescription Opioids $ Prescription Sedatives (Tranquilizers, Depressants) $ Prescription Stimulants $ Psilocybin $ Rohypnol® (Flunitrazepam) $ Salvia $ Steroids (Anabolic) $ Synthetic Cannabinoids (“K2”/”Spice”) $ Synthetic Cathinones (“Bath Salts”) PAGE | 53 Sources cited in this Appendix are: $ Drug Enforcement Administration’s Drug Facts Sheets1 $ Inhalant Addiction Treatment’s Dangers of Mixing Inhalants with Alcohol and Other Drugs2 $ National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) Alcohol’s Effects on the Body3 $ National Institute on Drug Abuse’s (NIDA’s) Commonly Abused Drugs4 $ NIDA’s Treatment for Alcohol Problems: Finding and Getting Help5 $ National Institutes of Health (NIH) National Library of Medicine’s Alcohol Withdrawal6 $ Rohypnol® Abuse Treatment FAQs7 $ Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Keeping Youth Drug Free8 $ SAMHSA’s Center for Behavioral Health Statistics and Quality’s (CBHSQ’s) Results from the 2015 National Survey on Drug Use and Health: Detailed Tables9 The substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15.10 Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States, their relative abuse potential, and likelihood of causing dependence when abused.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Slipping a Mickey? Facts Around Drugs, Alcohol and Sexual Assault
    Slipping a Mickey? Facts around drugs, alcohol and sexual assault DR CATHY STEPHENSON OCTOBER 2011 Slipping a Mickey? Phrase coined in late 19th century Chicago barman Mickey Finn used “knock-out” drops to incapacitate and rob his patrons Probably used chloral hydrate Centuries old practise – other drugs in historical literature include alcohol, barbiturates and scopolamine Recently much media coverage of “date rape” drugs and “drink-spiking” Case 1 18 yo girl, seen 7 hours post sexual assault Party, 5 RTDs in 2.5 hours – left one open on the table Shortly after felt “strange” Taken home by friend’s father In car, forced oral and vaginal penetration Diazepam found on hair samples, but not urine Case 2 16 year old girl Seen 6 months after SA Risk-taking behaviour prompted disclosure ETOH + marijuana + antidepressant Much more common scenario Case 3 23 year old girl Seen 20 hours after sexual assault In town with friends Drinking Offered a ride home Raped in car outside her flat DFSA? Victims subjected to non-consensual sexual activity while they are incapacitated or unconscious through the effect of alcohol or drugs (1) Thereby prevented from resisting and unable to give consent Ingestion can be voluntary, involuntary or both DFSA may be “proactive” or “opportunistic”(2) So how often does it really happen? No reliable data in literature Reporting of SA in general very low 21% of females and almost 5% of males in Australia report a lifetime history of sexual coercion(3) Analysis of 1200 urine samples from sexual
    [Show full text]
  • Bioanalytical Studies of Designer Benzodiazepines
    From DEPARTMENT OF LABORATORY MEDICINE Karolinska Institutet, Stockholm, Sweden BIOANALYTICAL STUDIES OF DESIGNER BENZODIAZEPINES Madeleine Pettersson Bergstrand Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Eprint AB © Madeleine Pettersson Bergstrand, 2018 ISBN 978-91-7831-063-0 Front page illustration: Sandra Eriksson Bioanalytical studies of designer benzodiazepines THESIS FOR DOCTORAL DEGREE (Ph.D.) The thesis will be defended at 4X, Alfred Nobels allé 8, Huddinge Friday, May 25, 2018 at 09.00 a.m. By Madeleine Pettersson Bergstrand Principal Supervisor: Opponent: Prof. Anders Helander Ass. Prof. Elisabeth Leere Øiestad Karolinska Institutet Oslo University Hospital Department of Laboratory Medicine Department of Forensic Sciences Division of Clinical Chemistry Clinic for Laboratory medicine Co-supervisor: Examination Board: Prof. Olof Beck Prof. Åsa Emmer Karolinska Institutet KTH Royal Institute of Technology Department of Laboratory Medicine Department of Chemistry Division of Clinical Pharmacology Division of Applied Physical Chemistry Docent Stefan Borg Karolinska Institutet Department of Clinical Neuroscience Docent Pierre Lafolie Karolinska Institutet Department of Medicine Division of Clinical Epidemiology ABSTRACT The fast appearance of benzodiazepine analogues, referred to as new psychoactive substance (NPS) or designer benzodiazepines, requires the continuous update of detection methods in order to keep up with the latest drugs on the recreational drug market. Moreover, as usually only limited information on toxicity and excretion patterns of these new drugs exists, this needs to be evaluated to report on adverse effects and to determine suitable targets for drug testing. Urine drug testing usually involves screening using immunoassay followed by confirmation of positive screening results using mass spectrometric (MS) methods.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrPROPOFOL Propofol Injectable Emulsion, BP 1% w/v 10 mg/mL Intravenous Emulsion – Anaesthetic - Sedative Baxter Corporation Date of Revision: Mississauga, Ontario September 29, 2017 L5N 0C2 Submission Control No: 207653 PROPOFOL Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]
  • Laws 2021, LB236, § 4
    LB236 LB236 2021 2021 LEGISLATIVE BILL 236 Approved by the Governor May 26, 2021 Introduced by Brewer, 43; Clements, 2; Erdman, 47; Slama, 1; Lindstrom, 18; Murman, 38; Halloran, 33; Hansen, B., 16; McDonnell, 5; Briese, 41; Lowe, 37; Groene, 42; Sanders, 45; Bostelman, 23; Albrecht, 17; Dorn, 30; Linehan, 39; Friesen, 34; Aguilar, 35; Gragert, 40; Kolterman, 24; Williams, 36; Brandt, 32. A BILL FOR AN ACT relating to law; to amend sections 28-1202 and 69-2436, Reissue Revised Statutes of Nebraska, and sections 28-401 and 28-405, Revised Statutes Cumulative Supplement, 2020; to redefine terms, change drug schedules, and adopt federal drug provisions under the Uniform Controlled Substances Act; to provide an exception to the offense of carrying a concealed weapon as prescribed; to define a term; to change provisions relating to renewal of a permit to carry a concealed handgun; to provide a duty for the Nebraska State Patrol; to eliminate an obsolete provision; to harmonize provisions; and to repeal the original sections. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2020, is amended to read: 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires: (1) Administer means to directly apply a controlled substance by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (2) Agent means an authorized person who acts on behalf of or at the direction of another person but does not include a common or contract carrier, public warehouse keeper, or employee of a carrier or warehouse keeper; (3) Administration means the Drug Enforcement Administration of the United States Department of Justice; (4) Controlled substance means a drug, biological, substance, or immediate precursor in Schedules I through V of section 28-405.
    [Show full text]
  • Focus on Benzodiazepines
    Graylands Hospital Drug Bulletin Focus on Benzodiazepines North Metropolitan Health Service – Mental Health March 2015 Vol 22 No.1 ISSN 1323–1251 The Non -BZD hypnotics such as zolpidem and Introduction zopiclone (Z-drugs) are more selective for the alpha-1 subclass which seems to drive sleepiness but not anti-anxiety. Benzodiazepines (BZDs) are one of the most commonly prescribed medications for the treatment Table 1: BZDs and relative half-lives9,10 of insomnia and anxiety. 1 They are also frequently used to treat psychiatric emergencies, epilepsy, severe muscle spasm, acute alcohol withdrawal, Drug name Half -life (hours) anaesthesia and intensive care. Short -acting Triazolam 2 However, the use of BZDs is often controversial as Alprazolam 6-12 they are widely acknowledged to be addictive and Oxazepam 4-15 withdrawal symptoms can occur after 4-6 weeks of Temazepam 8-22 continuous use. This had led to the recommendation Medium -acting that they should not be used as hypnotics or Bromazepam 10 -20 anxiolytics for longer than 4 weeks. 2 In older age, Lorazepam 10 -20 BZDs also have serious adverse effects, including increased risk of falls, road traffic accidents and Long -acting 3,4 Clobazam 12 -60 cognitive impairment. Clonazepam 18 -50 More recently the risks of long term BZD use have Diazepam 20 -100 received greater focus with new evidence Flunitrazepam 18 -26 demonstrating a link between BZD use and the Nitrazepam 15 -38 5 development of Alzheimer’s disease and also 6 increased risk of mortality. Benzodiazepine use in Psychiatry Given the wide spread usage of these medications and the associated risk, this bulletin reviews BZDs Sleep disorders with particular emphasis upon adverse effects, dependence and abuse potential.
    [Show full text]
  • Function of Y-Aminobutyrate Type a Receptors R
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 3658-3662, April 1995 Neurobiology Mutant mice lacking the y isoform of protein kinase C show decreased behavioral actions of ethanol and altered function of y-aminobutyrate type A receptors R. ADRON HARRIS*, SUSAN J. MCQUILKIN*, RICHARD PAYLORt, ASA ABELIOVICHt, SUSUMU TONEGAWA§, AND JEANNE M. WEHNERt *Denver Veterans Affairs Medical Center and Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262-0236; tlnstitute for Behavioral Genetics and School of Pharmacy, University of Colorado, Boulder, CO 80309; tCenter for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and §Howard Hughes Medical Institute at the Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139 Contributed by Susumu Tonegawa, January 18, 1995 ABSTRACT Calcium/phospholipid-dependent protein The role of PKC in the function of GABAA receptors is also kinase (protein kinase C, PKC) has been suggested to play a controversial. Activation of PKC by phorbol esters markedly role in the sensitivity of y-aminobutyrate type A (GABAA) inhibits function of GABAA receptors expressed in oocytes receptors to ethanol. We tested a line of null mutant mice that (13-15) but has less effect on native GABAA receptors ofbrain lacks the 'y isoform of PKC (PKCy) to determine the role of membranes (14, 16). In contrast, the function of recombinant this brain-specific isoenzyme in ethanol sensitivity. We found GABAA receptors expressed in fibroblasts is enhanced by that the mutation reduced the amount of PKCy immunore- catalytically active PKC (17). activity in cerebellum to undetectable levels without altering Thus, the questions of whether GABAA receptor function is the levels ofthe a, 8j3, or Pu isoforms ofPKC.
    [Show full text]
  • The Detection of Date Rape Drug Residues Using X-Ray Diffraction Emily A
    The Detection of Date Rape Drug Residues Using X-Ray Diffraction Emily A. Walsh Forensic Science Department Dr. Virginia M. Maxwell Abstract A predominant problem investigators and forensic scientists encounter is difficulty in the detection of date rape drugs in a drug facilitated sexual assault (DFSA) victim’s system, more specifically their blood, hair, and urine. After a matter of hours, these fast acting drugs have little chance of being detected with modern toxicological techniques due to their rapid metabolism by the body. Proving the use of these drugs can be very hard to establish due to the challenge of detection. This project utilized X-ray diffraction (XRD) in order to detect and identify date rape drugs on various materials. The date rape drugs used for the purposes of this project were Gamma-Hydroxybutyric acid (GHB), Chloral Hydrate, Ketamine, Flunitrazepam (Rohypnol), and MDMA (Ecstasy). XRD has been implemented in many forensic science laboratories due to low cost, versatility, and the non-destructive nature of analysis. The focus of this research was to evaluate the use of XRD for the detection of date rape drug residues on clothing and in containers, such as those typically submitted as evidence in suspected DFSAs. Introduction major problem in suspected DFSA cases. The difficulty Numerous studies have been conducted on the detecting these drugs stems from a property called half-life. prevalence of sexual assault on college campuses. The Half-life is the period of time needed for the body to Campus Sexual Assault (CSA) Study conducted by the metabolize half the drug, resulting in the quantity of the National Institute of Justice provides statistics about these drug in the body to fall to half its value.
    [Show full text]